| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 289,564 | 72,197 |
| Net increase in cash, cash equivalents and restricted cash | 27,468 | 29,433 |
| Cash and cash equivalents at beginning of period | 98,165 | - |
| Cash and cash equivalents at end of period | 125,633 | - |
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)